M A Kowalkowski1, M A Mims2, R S Day3, X L Du3, W Chan4, E Y Chiao5. 1. Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA; Department of Medicine, Baylor College of Medicine, Houston, TX, USA; Houston Health Services Research and Development Center of Excellence, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA. Electronic address: marc.kowalkowski@carolinashealthcare.org. 2. Department of Medicine, Baylor College of Medicine, Houston, TX, USA. 3. Department of Epidemiology, Human Genetics, and Environmental Sciences, University of Texas School of Public Health, Houston, TX, USA. 4. Department of Biostatistics, University of Texas School of Public Health, Houston, TX, USA. 5. Department of Medicine, Baylor College of Medicine, Houston, TX, USA; Houston Health Services Research and Development Center of Excellence, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA.
Abstract
BACKGROUND: Hodgkin lymphoma (HL) incidence has increased since combined antiretroviral therapy (cART) introduction. It is unclear how different cART classes (e.g., protease inhibitors (PI), non-nucleoside reverse transcription inhibitors (NNRTI)) influence HL. This study aimed to determine the effects of cART duration on HL incidence among HIV-infected veterans. METHODS: We performed a retrospective cohort study utilizing the Veterans Affairs HIV Clinical Case Registry (1985-2010). HL cases were identified using ICD-9 codes (201.4-9). cART, PI, and NNRTI duration was the aggregate number of treatment days delivered. Incidence rates (IR) and rate ratios (IRR) were calculated from Poisson regression models to examine the effects of cART duration on HL. RESULTS: 31,576 cART users contributed 288,736 person-years (PY) and 211 HL cases (IR=7.3/10,000 person-years). HL incidence decreased from 25.1/10,000 PY (95%CI=18.9-33.4) within the first year of cART to 0.6/10,000 PY (95%CI=0.3-1.6) after ≥ 10 years. In multivariable models, each additional year of cART was associated with decreased HL incidence (IRR=0.80; 95%CI=0.75-0.86); similar effects were observed in models assessing HL incidence by PI and NNRTI. CONCLUSION: Our findings indicate long-term cART of any class is associated with decreased HL risk. High HL incidence directly following cART initiation supports a potential immune reconstitution mechanism in HIV-related HL. Further research is needed to evaluate the interaction between early cART, immune reconstitution, and HL.
BACKGROUND:Hodgkin lymphoma (HL) incidence has increased since combined antiretroviral therapy (cART) introduction. It is unclear how different cART classes (e.g., protease inhibitors (PI), non-nucleoside reverse transcription inhibitors (NNRTI)) influence HL. This study aimed to determine the effects of cART duration on HL incidence among HIV-infected veterans. METHODS: We performed a retrospective cohort study utilizing the Veterans Affairs HIV Clinical Case Registry (1985-2010). HL cases were identified using ICD-9 codes (201.4-9). cART, PI, and NNRTI duration was the aggregate number of treatment days delivered. Incidence rates (IR) and rate ratios (IRR) were calculated from Poisson regression models to examine the effects of cART duration on HL. RESULTS: 31,576 cART users contributed 288,736 person-years (PY) and 211 HL cases (IR=7.3/10,000 person-years). HL incidence decreased from 25.1/10,000 PY (95%CI=18.9-33.4) within the first year of cART to 0.6/10,000 PY (95%CI=0.3-1.6) after ≥ 10 years. In multivariable models, each additional year of cART was associated with decreased HL incidence (IRR=0.80; 95%CI=0.75-0.86); similar effects were observed in models assessing HL incidence by PI and NNRTI. CONCLUSION: Our findings indicate long-term cART of any class is associated with decreased HL risk. High HL incidence directly following cART initiation supports a potential immune reconstitution mechanism in HIV-related HL. Further research is needed to evaluate the interaction between early cART, immune reconstitution, and HL.
Authors: Eric A Engels; Ruth M Pfeiffer; James J Goedert; Phillip Virgo; Timothy S McNeel; Steven M Scoppa; Robert J Biggar Journal: AIDS Date: 2006-08-01 Impact factor: 4.177
Authors: Wei Jiang; Peter J Mikochik; Jin H Ra; Hanqin Lei; Keith T Flaherty; Jeffrey D Winkler; Francis R Spitz Journal: Cancer Res Date: 2007-02-01 Impact factor: 12.701
Authors: Joell J Gills; Jaclyn Lopiccolo; Junji Tsurutani; Robert H Shoemaker; Carolyn J M Best; Mones S Abu-Asab; Jennifer Borojerdi; Noel A Warfel; Erin R Gardner; Matthew Danish; M Christine Hollander; Shigeru Kawabata; Maria Tsokos; William D Figg; Patricia S Steeg; Phillip A Dennis Journal: Clin Cancer Res Date: 2007-09-01 Impact factor: 12.531
Authors: Hans-Jürgen Stellbrink; Eric Le Fevre; Andrew Carr; Michael S Saag; Geoffrey Mukwaya; Silvia Nozza; Srinivas Rao Valluri; Manoli Vourvahis; Alex R Rinehart; Lynn McFadyen; Carl Fichtenbaum; Andrew Clark; Charles Craig; Annie F Fang; Jayvant Heera Journal: AIDS Date: 2016-05-15 Impact factor: 4.177
Authors: Connie G Chiu; Danielle Smith; Kate A Salters; Wendy Zhang; Steve Kanters; David Milan; Julio S G Montaner; Andy Coldman; Robert S Hogg; Sam M Wiseman Journal: BMC Cancer Date: 2017-04-14 Impact factor: 4.430
Authors: Francisco J Hernández-Walias; Esther Vázquez; Yolanda Pacheco; José M Rodríguez-Fernández; María J Pérez-Elías; Fernando Dronda; José L Casado; Ana Moreno; José M Hermida; Carmen Quereda; Asunción Hernando; Francisco Tejerina-Picado; Víctor Asensi; María J Galindo; Manuel Leal; Santiago Moreno; Alejandro Vallejo Journal: J Clin Med Date: 2020-03-11 Impact factor: 4.241